Menopausal hormone therapy in 2012

Best practice clinical approaches in 2012 require the consideration of menopausal hormone therapy (MHT or HRT) for peri and early postmenopausal women troubled with hot flushes, night sweats, insomnia, vaginal dryness and urinary frequency.

Use of HRT declined dramatically following the 2002 NIH announcement that HRT increases breast cancer risk by 26%.

Breast cancer and CVD prevention
Close examination of the initial trial (WHI) indicates the breast cancer finding (after the subjects had been treated for five years) equated, in Australian terms, to one